Huntington's disease

Current Treatment Options in Neurology

Volumn 8, Issue 3, 2006, Pages 236-244

  Higgins Jr , Donald S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONAZEPAM; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOT DERIVATIVE; GALANTAMINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; RIFAMPICIN; RILUZOLE; RIVASTIGMINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRABENAZINE; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABSENCE; AKATHISIA; ANKLE EDEMA; ANOREXIA; ANTICHOLINERGIC SYNDROME; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELUSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIETARY INTAKE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG COST; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; DYSTONIA; EDEMA; EJACULATION DISORDER; EPILEPTIC STATE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; HYPERTHERMIA; INVOLUNTARY MOVEMENT; LIBIDO DISORDER; LIFESTYLE; LIVEDO RETICULARIS; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE TWITCH; MYOCLONUS; NAUSEA; NERVE CELL DEGENERATION; OCCUPATIONAL THERAPY; PARKINSONISM; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHYSIOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; REHABILITATION MEDICINE; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREMOR; UNITED STATES; VOMITING;

EID: 33645829846     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-006-0014-x     Document Type: Review

References (47)

1. Harper PS: The epidemiology of Huntington's disease. Hum Genet 1992, 89:365-376.
2. Feigin A, Kieburtz K, Shoulson I: Treatment of Huntington's disease and other choreic disorders. In Treatment of Movement Disorders. Edited by Kurlan R. Philadelphia, PA: JB Lippincott; 1995:337-364.
3. Foroud T, Gray J, Ivashina J, Conneally PM: Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry 1999, 66:52-56.
4. Lanska DJ, Lavine L, Lanska MJ, Schoenberg BS: Huntington's disease mortality in the United States. Neurology 1988, 38:769-772.
5. Caine ED, Shoulson I: Psychiatric syndromes in Huntington's disease. Am J Psychiatry 1983, 140:728-733.
6. Mindham RH, Steele C, Folstein MF, Lucas J: A comparison of the frequency of major affective disorder in Huntington's disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985, 48:1172-1174.
7. Schoenfeld M, Myers RH, Cupples LA, et al.: Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984, 47:1283-1287.
8. Shoulson I: Huntington's disease: cognitive and psychiatric features. Neuropsychiatry Neuropsychol Behav Neurol 1990, 3:15-22.
9. Rosenblatt A, Leroi I: Neuropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics 2000, 41:24-30.
10. Bittenbender JB, Quadfasel FA: Rigid and akinetic forms of Huntington's chorea. Arch Neural 1962, 7:37-50.
11. Conneally PM: Huntington disease: genetics and epidemiology. Am J Hum Genet 1984, 36:506-526.
12. Ranen NG, Stine OC, Abbott MH, et al.: Anticipation and instability of IT-15 (CAG)N repeats in parent offspring pairs with Huntington disease. Am J Hum Genet 1995, 57:593-602.
13. Snell RG, MacMillan JC, Cheadle JP, et al.: Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993, 4:393-397.
14. Siesling S, Vegter-van der Vlis M, Roos RA: Juvenile Huntington disease in the Netherlands. Pediatr Neurol 1997, 17:37-43.
15. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
16. Lucotte G, Turpin JC, Riess O, et al.: Confidence intervals for predicted age of onset, given the size of (CAG)n repeat, in Huntington's disease. Hum Genet 1995, 95:231-232.
17. Brinkman RR, Mezei MM, Theilmann J, et al.: The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997, 60:1202-1210.
18. Nance MA, UHDGT Group: Genetic testing of children at risk for Huntington's chorea. Neurology 1997, 49:1048-1053.
19. Paulson GW, Prior TW: Issues related to DNA testing for Huntington's disease in symptomatic patients. Semin Neurol 1997, 17:235-238.
20. Meiser B, Dunn S: Psychological impact of genetic testing for Huntington's disease: an update of the literature. J Neurol Neurosurg Psychiatry 2000, 69:574-578.
21. Aylward EH, Li Q, Stine OC, et al.: Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997, 48:394-399.
22. Feigin A, Kieburtz K, Como P, et al.: Assessment of coenzyme Q10 tolerability in Huntington's Disease. Mov Disord 1996, 11:321-323.
23. Bachoud-Levi AC, Remy P, Nguyen JP, et al.: Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
24. Hantraye P, Riche D, Maziere M, Isacson O: Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci U S A 1992, 89:4187-4191.
25. Galpern WR, Burns LH, Deacon TW, et al.: Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 1996, 140:1-13.
26. Anderson KD, Panayotatos N, Corcoran TL, et al.: Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington Disease. PNAS 1996, 93:7346-7351.
27. Kordower JH,Chen EY, Winkler C, et al.: Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice:trophic and trophic effects in a rodent model of Huntington's disease. J Comp Neurol 1997, 387:96-113.
28. Barr AN, Fischer JH,Koller WC, et al.: Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988, 38:84-88.
29. Guthrie SK: Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health Syst. Pharm 2002, 59(Suppl 5):S19-S24.
30. Bonelli RM, Mahnert FA, Niederwieser G: Olanzapine for Huntington's disease:an open label study. Clin Neuropharmacol 2002, 25:263-265.
31. Bergman RN, Ader M: Atypical antipsychotics and glucose homeostatis. J Clin Psychiatry 2005, 66:504-514.
32. Verhagen Metman L, Morris MJ, Farmer C, et al.: Huntington's disease:a randomized, controlled trial using the NMDA antagonist amantadine. Neurology 2002, 59:694-699.
33. Huntington Study Group: Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003, 61:1551-1556.
34. Naarding P, Kremer HP, Zitman FG: Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry 2001, 16:439-445.
35. Como PG, Rubin AJ, O'Brien CF, et al.: A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997, 12:397-401.
36. Isbister GK, Buckley NA: The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005, 28:205-214.
37. Armon C, Shin C, Miller P, et al.: Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996, 47:626-635.
38. Grove VE Jr, Quintanilla J, DeVaney GT: Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000, 343:973-974.
39. Carella F, Scaioli V, Ciano C, et al.: Adult onset myoclonic Huntington's disease Mov Disord 1993, 8:201-205.
40. de Tommaso M, Specchio N, Sciruicchio O, et al.: Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004, 19:1516-1518.
41. Bilney B, Morris ME, Perry A: Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review. Neurorehabil Neural Repair 2003, 17:12-24.
42. Moskowitz CB, Marder K: Palliative care for people with late-stage Huntington's disease. Neurol Clin 2001, 19:849-865.
43. Angus F, Burakoff R: The percutaneous endoscropic gastrostonomy tube. Medical and ethical issues in placement. Am J Gastroentenol 2003, 98:272-277.
44. Huntington Study Group: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
45. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington's disease: a randomized controlled trial. Neurology 2006, 66:366-372.
46. Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358-362.
47. Puri BK, Leavitt BR, Hayden MR, et al.: Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005, 65:286-292.